JPMorgan Chase & Co. Issues Pessimistic Forecast for Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) had its target price decreased by equities research analysts at JPMorgan Chase & Co. from $19.00 to $17.00 in a research note issued on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 123.10% from the stock’s current price.

Other research analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, October 11th. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Enanta Pharmaceuticals in a research report on Wednesday, September 23rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Thursday, October 15th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Enanta Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $19.00.

Read Our Latest Stock Analysis on ENTA

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ:ENTA opened at $7.62 on Friday. The company’s 50-day moving average is $11.48 and its 200 day moving average is $12.97. The company has a market capitalization of $222.20 million, a P/E ratio of -3.24 and a beta of 0.75. Enanta Pharmaceuticals has a fifty-two week low of $7.56 and a fifty-two week high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The biotechnology company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.09). Enanta Pharmaceuticals had a negative net margin of 108.33% and a negative return on equity of 64.32%. The company had revenue of $12.87 million for the quarter, compared to the consensus estimate of $14.62 million. As a group, research analysts predict that Enanta Pharmaceuticals will post -2.24 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Quantinno Capital Management LP increased its holdings in Enanta Pharmaceuticals by 4.9% in the 1st quarter. Quantinno Capital Management LP now owns 35,122 shares of the biotechnology company’s stock worth $444,000 after acquiring an additional 1,627 shares during the last quarter. Legal & General Group Plc bought a new stake in Enanta Pharmaceuticals in the 2nd quarter valued at about $41,000. Clearstead Trust LLC purchased a new stake in Enanta Pharmaceuticals during the second quarter valued at about $74,000. Wellington Management Group LLP lifted its holdings in Enanta Pharmaceuticals by 8.9% during the second quarter. Wellington Management Group LLP now owns 81,633 shares of the biotechnology company’s stock valued at $1,190,000 after purchasing an additional 6,673 shares during the last quarter. Finally, Alps Advisors Inc. lifted its holdings in Enanta Pharmaceuticals by 29.8% during the third quarter. Alps Advisors Inc. now owns 38,315 shares of the biotechnology company’s stock valued at $505,000 after purchasing an additional 8,807 shares during the last quarter. Institutional investors own 94.99% of the company’s stock.

Top Enanta Pharmaceuticals Stories

Here are a few of the latest stories about ENTA:

  • Positive Sentiment: HC Wainwright maintained its Buy rating and $20 price target, while raising its FY2027–FY2030 earnings estimates to reflect smaller projected losses. This signals improved longer-term expectations, though the forecasts still show losses. MarketBeat report
  • Neutral Sentiment: JPMorgan cut its price target to $17 from $19 but kept an Overweight rating. The lower target is a negative revision, while the rating and implied upside from the cited $7.62 share price remain supportive.
  • Negative Sentiment: Enanta’s latest reported quarter missed expectations: its loss per share was wider than analysts forecast, and revenue came in below estimates. The results may weigh on sentiment amid the analyst updates. MarketBeat earnings information

About Enanta Pharmaceuticals

(Get Free Report)

Enanta Pharmaceuticals, Inc. is a biotechnology company based in Watertown, Massachusetts, that discovers and develops small-molecule medicines. Its research has focused on infectious diseases and inflammatory conditions, including respiratory syncytial virus (RSV), hepatitis B and immunology. Enanta’s work with AbbVie contributed to the discovery of glecaprevir, an antiviral used with pibrentasvir in the hepatitis C treatment Mavyret. The collaboration reflects the company’s history of applying its drug-discovery expertise to antiviral therapies.

Further Reading

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.